GSK, Novartis complete major three-part transaction

Monday, March 2, 2015

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis’ global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

[Read More]

Grifols, Aradigm sign licensing agreement to develop, commercialize Pulmaquin

Wednesday, May 22, 2013

Grifols, a global healthcare company, and Aradigm, an emerging specialty pharmaceutical company focused severe respiratory diseases, have signed an exclusive worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed phase IIb clinical trials in BE patients with Pulmaquin and Lipoquin.

[Read More]

Grifols initiates safety study of inhaled alpha1-proteinase inhibitor for CF

Thursday, July 19, 2012

Grifols, a global healthcare company based in Barcelona, Spain, plans to initiate a safety trial of a novel, inhaled formulation of alpha1-proteinase inhibitor [human] later this year.  In April, the FDA granted orphan drug designation for Grifols’ inhaled alpha1 formulation as a treatment for cystic fibrosis, an inherited disease that can cause life-threatening lung infections. Orphan drug designation is granted to encourage the development of treatments that prevent, diagnose or treat rare diseases that affect fewer than 200,000 people per year in the U.S.

[Read More]